The effects of PPAR-γ agonist pioglitazone on anxiety and depression-like behaviors in lipopolysaccharide injected rats

References

• Abareshi, A., et al., 2016. The effects of captopril on lipopolysaccharide induced learning and memory impairments and the brain cytokine levels and oxidative damage in rats. Life sciences, 167, 46–56.
   PubMed Web of Science ®Google Scholar
• Anaeigoudari, A., et al., 2016. Neuronal nitric oxide synthase has a role in the detrimental effects of lipopolysaccharide on spatial memory and synaptic plasticity in rats. Pharmacological reports, 68(2), 243–249.
   PubMed Web of Science ®Google Scholar
• Azizi-Malekabadi, H., et al., 2015. Deletion of ovarian hormones induces a sickness behavior in rats comparable to the effect of lipopolysaccharide. Neurology research international, 2015, 1.
   Web of Science ®Google Scholar
• Baghcheghi, Y., et al., 2016. Protective effect of PPARγ agonists on cerebellar tissues oxidative damage in hypothyroid rats. Neurology research international, 2016:1952561.
   PubMed Web of Science ®Google Scholar
• Baghcheghi, Y., et al., 2019. Effects of PPAR-gamma agonist, pioglitazone on brain tissues oxidative damage and learning and memory impairment in juvenile hypothyroid rats. International journal of neuroscience, 129(10), 1024–1038.
   PubMed Web of Science ®Google Scholar
• Bargi, R., et al., 2017. The effects of thymoquinone on hippocampal cytokine level, brain oxidative stress status and memory deficits induced by lipopolysaccharide in rats. Cytokine, 96, 173–184.
   PubMed Web of Science ®Google Scholar
• Beheshti, F., et al., 2017. The effects of Nigella sativa extract on hypothyroidism-associated learning and memory impairment during neonatal and juvenile growth in rats. Nutritional neuroscience, 20(1), 49–59.
   PubMed Web of Science ®Google Scholar
• Beheshti, F., et al., 2019. The effects of PPAR-γ agonist pioglitazone on hippocampal cytokines, brain-derived neurotrophic factor, memory impairment, and oxidative stress status in lipopolysaccharide-treated rats. Cytokine, 113, 347–355.
   PubMed Web of Science ®Google Scholar
• Benedetti, E., et al., 2018. PPARs in neurodegenerative and neuroinflammatory pathways. Current Alzheimer research, 15(4), 336–344.
   PubMed Web of Science ®Google Scholar
• Burgaz, S., et al., 2019. Development of an oral treatment with the PPAR-gamma-Acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson's disease. Molecules, 24:pii: E2702.
   Web of Science ®Google Scholar
• Carola, V., et al., 2002. Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice. Behavioural brain research, 134(1–2), 49–57.
   PubMed Web of Science ®Google Scholar
• Chourbaji, S., et al., 2006. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiology of disease, 23(3), 587–594.
   PubMed Web of Science ®Google Scholar
• Contreras, C.M., et al., 2001. The lowest effective dose of fluoxetine in the forced swim test significantly affects the firing rate of lateral septal nucleus neurones in the rat. Journal of psychopharmacology, 15(4), 231–236.
   PubMed Web of Science ®Google Scholar
• Dantzer, R., et al., 2011. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology, 36(3), 426–436.
   PubMed Web of Science ®Google Scholar
• Dowlati, Y., et al., 2010. A meta-analysis of cytokines in major depression. Biological psychiatry, 67(5), 446–457.
   PubMed Web of Science ®Google Scholar
• Dunn, A.J., 2006. Cytokine activation of the HPA axis. Annals of the New York academy of sciences, 917(1), 608–617.
   Google Scholar
• Feinstein, D.L., 2003. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes technology and therapeutics, 5, 67–73.
   PubMedGoogle Scholar
• Girnun, G.D., et al., 2002. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Molecular endocrinology, 16(12), 2793–2801.
   PubMedGoogle Scholar
• Habeeb, A., 1972. [37] Reaction of protein sulfhydryl groups with Ellman's reagent. Methods in enzymology, 25, 457–464.
   PubMedGoogle Scholar
• Harrison, N.A., et al., 2014. Peripheral inflammation acutely impairs human spatial memory via actions on medial temporal lobe glucose metabolism. Biological psychiatry, 76(7), 585–593.
   PubMed Web of Science ®Google Scholar
• Held, T.K., et al., 1999. Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1. Infection and immunity, 67(1), 206–212.
   PubMed Web of Science ®Google Scholar
• Heneka, M.T., et al., 2005. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice. Brain, 128(6), 1442–1453.
   PubMedGoogle Scholar
• Hosseini, M., et al., 2015. Effects of the hydro-alcoholic extract of Nigella sativa on scopolamine-induced spatial memory impairment in rats and its possible mechanism. Chinese journal of integrative medicine, 21(6), 438–444.
   PubMed Web of Science ®Google Scholar
• Houseknecht, K.L., Cole, B.M., and Steele, P.J., 2002. Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: a review. Domestic animal endocrinology, 22(1), 1–23.
   PubMed Web of Science ®Google Scholar
• Hritcu, L. and Gorgan, L.D., 2014. Intranigral lipopolysaccharide induced anxiety and depression by altered BDNF mRNA expression in rat hippocampus. Progress in neuro-psychopharmacology and biological psychiatry, 51, 126–132.
   PubMed Web of Science ®Google Scholar
• Jiang, L.Y., et al., 2012. PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS neuroscience & therapeutics, 18, 659–666.
   PubMed Web of Science ®Google Scholar
• Kang, A., et al., 2011. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. Journal of neuroinflammation, 8(1), 100.
   PubMedGoogle Scholar
• Kaur, B., Singh, N., and Jaggi, A.S., 2009. Exploring mechanism of pioglitazone‐induced memory restorative effect in experimental dementia. Fundamental & clinical pharmacology, 23, 557–566.
   PubMed Web of Science ®Google Scholar
• Kemp, D.E., et al., 2012. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. Journal of affective disorders, 136(3), 1164–1173.
   PubMed Web of Science ®Google Scholar
• Kemp, D.E., Ismail-Beigi, F., and Calabrese, J.R., 2009. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. American journal of psychiatry, 166(5), 619–619.
   PubMed Web of Science ®Google Scholar
• Kraeuter, A.K., Guest, P.C., and Sarnyai, Z., 2019. The open field test for measuring locomotor activity and anxiety-like behavior. Methods in molecular biology (Clifton, NJ), 1916, 99–103.
   PubMedGoogle Scholar
• Krishnan, K.R., et al., 1991. Hippocampal abnormalities in depression. The journal of neuropsychiatry and clinical neurosciences, 3(4), 387–391.
   PubMed Web of Science ®Google Scholar
• Kumar, A., Vashist, A., and Kumar, P., 2010. Potential role of pioglitazone, caffeic acid and their combination against fatigue syndrome-induced behavioural, biochemical and mitochondrial alterations in mice. Inflammopharmacology, 18(5), 241–251.
   PubMedGoogle Scholar
• Lefebvre, P., et al., 2006. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. Journal of clinical investigation, 116(3), 571–580.
   PubMed Web of Science ®Google Scholar
• Leonard, B.E., 2001. The immune system, depression and the action of antidepressants. Progress in neuro-psychopharmacology and biological psychiatry, 25(4), 767–780.
   PubMed Web of Science ®Google Scholar
• Machado, M.M.F., et al., 2019. PPAR-gamma agonist pioglitazone reduces microglial proliferation and NF-kappaB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease. Pharmacological reports, 71(4), 556–564.
   PubMed Web of Science ®Google Scholar
• Madesh, M. and Balasubramanian, K., 1997. A microtiter plate assay for superoxide using MTT reduction method. Indian journal of biochemistry and biophysics, 34(6), 535–539.
   PubMed Web of Science ®Google Scholar
• Maes, M., et al., 2011. Depression’s multiple comorbidities explained by (neuro) inflammatory and oxidative & nitrosative stress pathways. Neuro endocrinology letters, 32(1), 7–24.
   PubMed Web of Science ®Google Scholar
• Maes, M., et al., 2012. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC medicine, 10(1), 66.
   PubMedGoogle Scholar
• Miller, A.H., 2010. Depression and immunity: a role for T cells? Brain, behavior, and immunity, 24(1), 1–8.
   PubMed Web of Science ®Google Scholar
• Mirza, R. and Sharma, B., 2019. A selective peroxisome proliferator-activated receptor-gamma agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. Chemico-biological interactions, 311, 108758.
   PubMed Web of Science ®Google Scholar
• Neamati, A., et al., 2014. The effects of Valeriana officinalis L. hydro-alcoholic extract on depression like behavior in ovalbumin sensitized rats. Journal of pharmacy and bioallied sciences, 6, 97.
   PubMedGoogle Scholar
• Pancani, T., et al., 2009. Distinct modulation of voltage‐gated and ligand‐gated Ca2+ currents by PPAR‐γ agonists in cultured hippocampal neurons. Journal of neurochemistry, 109(6), 1800–1811.
   PubMed Web of Science ®Google Scholar
• Pedersen, W.A., et al., 2006. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Experimental neurology, 199(2), 265–273.
   PubMed Web of Science ®Google Scholar
• Petit-Demouliere, B., Chenu, F., and Bourin, M., 2005. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology, 177(3), 245–255.
   PubMed Web of Science ®Google Scholar
• Płóciennikowska, A., et al., 2015. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cellular and molecular life sciences, 72(3), 557–581.
   PubMed Web of Science ®Google Scholar
• Rosa, A.O., et al., 2008. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in neuro-psychopharmacology and biological psychiatry, 32(6), 1549–1556.
   PubMed Web of Science ®Google Scholar
• Sauerbeck, A., et al., 2011. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Experimental neurology, 227(1), 128–135.
   PubMed Web of Science ®Google Scholar
• Seibenhener, M.L. and Wooten, M.C., 2015. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. Journal of visualized experiments, e52434.
   PubMed Web of Science ®Google Scholar
• Sharp, L.K. and Lipsky, M.S., 2002. Screening for depression across the lifespan. American family physician, 66(6), 1001–1008.
   PubMed Web of Science ®Google Scholar
• Swiergiel, A.H. and Dunn, A.J., 2007. Effects of interleukin-1β and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests. Pharmacology biochemistry and behavior, 86(4), 651–659.
   PubMed Web of Science ®Google Scholar
• Thakur, P. and Rana, A.C., 2013. Effect of Cissampelos pareira leaves on anxiety-like behavior in experimental animals. Journal of traditional and complementary medicine, 3(3), 188–193.
   PubMedGoogle Scholar
• Yin, Q.-Q., et al., 2013. Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PLoS One, 8(3), e59313.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2019. Pioglitazone prevents sevoflurane-induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPARgamma. Molecular medicine reports, 19, 3815–3822.
   PubMed Web of Science ®Google Scholar
• Zhao, X., et al., 2007. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator‐activated receptor γ in microglia/macrophages. Annals of neurology, 61(4), 352–362.
   PubMed Web of Science ®Google Scholar